1. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014; (1):CD009593.
Article
2. Jeon D. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in South Korea. Tuberc Respir Dis. 2017; 80:336–343.
Article
3. Huh HJ, Jeong BH, Jeon K, Koh WJ, Ki CS, Lee NY. Performance evaluation of the Xpert MTB/RIF assay according to its clinical application. BMC Infect Dis. 2014; 14:589.
Article
4. Marlowe EM, Novak-Weekley SM, Cumpio J, Sharp SE, Momeny MA, Babst A, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol. 2011; 49:1621–1623.
5. Pang Y, Lu J, Su B, Zheng H, Zhao Y. Misdiagnosis of tuberculosis associated with some species of nontuberculous mycobacteria by GeneXpert MTB/RIF assay. Infection. 2017; 45:677–681.
Article
6. Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives. Tuberc Respir Dis. 2016; 79:74–84.
Article
7. Pang Y, Tan Y, Chen J, Li Y, Zheng H, Song Y, et al. Diversity of nontuberculous mycobacteria in eastern and southern China: a cross-sectional study. Eur Respir J. 2017; 49:1601429.
8. Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis. 2017; 64:309–316.
9. Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother. 2008; 52:2019–2026.
10. Cepheid. Xpert MTB/RIF assay, 301-1404 Rev. B [package insert]. Sunnyvale: Cepheid;2015.